A joint event: IV Annual IMPPC Conference/1st ICO-IDIBELL Hereditary Cancer Program Meeting

CosmoCaixa, Barcelona 14-15 March 2013



Wednesday 13 March

13.00 - 18.15

Jornada Nacional de Grupos de Trabajo en Cáncer Hereditario

National Meeting for Spanish groups working on Hereditary Cancer.   This meeting is free but registration is obligatory, most of the sessions will be in Spanish.  If you wish to attend you must sign up separately for this meeting. 

Link to go to registration for the National Meeting


Public Lecture at CosmoCaixa

Herencia y Cáncer: lo que sabemos y cómo lo vivimos

Conference in Spanish: Heredity and Cancer: What we know and How to Live with it

Carlos Cordón-Cardó

Professor and Chair, Pathology
Professor Genetics and Genomic Sciences
Professor Oncological Sciences
Ichan School of Medicine at Mount Sinai Hospital, New York

Thursday 14 March

09.00 - 10.00

Opening Session

The objective of this opening session is to give a broad vision of the field, provide the audience with a brief background of the different topics that will be covered in the conference and highlight present challenges. 

09.00-09.15 Welcome
                    Gabriel Capellá and Manuel Perucho
09.15-10.00 Plenary Lecture
                    Stephen B. Gruber
                    USC Norris Comprehensive Cancer Center, University of Southern California, USA
                    The Past, Present and Future of Clinical Cancer Genetics


Session 1: Cancer Biology through the Study of Hereditary Cancer GenesChair: Miguel Angel Pujana and Hans Vasen

Hereditary cancer genes participate in key biological pathways and cellular functions governing cell behavior: signal transduction pathways, DNA stability and repair pathways, cell cycle control, hypoxia, angiogenesis, apoptosis, and other aspects of cellular metabolism. What do we know about cancer thanks to the study of hereditary cancer genes? Can a comprehensive global vision of hereditary cancer provide some new insight into cancer biology?

10.00-10.05     Introduction

10.05-10.35     Eric R. Fearon, University of Michigan, USA
                        Modeling the Molecular Pathogenesis of Colorectal Cancer
10.35-11.05      Jordi Surrallés, UAB (Autonomous University of Barcelona) and CIBERER, Spain
                        Fanconi anemia: a paradigm of cancer prone syndrome
11.05-11.25      Aguirre A de Cubas Spanish National Cancer Center (CNIO), Spain
                        DNA Methylation profiling of pheochromocytoma and
                        paraganglioma. Adding more pieces of the puzzle





Session 2: New Methodological Approaches Applied to Hereditary Cancer AnalysisChair: Conxi Lázaro and Stephen Gruber

New genomic technologies such as Next Generation Sequencing or chip-based analysis are providing new opportunities in the hereditary cancer field: better cost-effective genetic diagnoses; discovering new genes involved in hereditary cancer; better understanding of the generation of hereditary tumors, etc. This session will provide different examples of how current applications of these new technologies make the field advance.

12.10-12.15     Introduction
12.15-12.45     Chris Mattocks, National Genetics Reference Laboratory, UK
                         Diagnostic implementation of next generation sequencing
12.45-13.15     Emmanouil T. Dermitzakis, CMU / University of Geneva Medical School
                        Genetics of cellular phenotypes in humans
13.15 -13.35    Balazs Jori
                        Maastricht University Medical Centre, The Netherlands
                        Targeted Exome Sequencing in Searching Additional Genetic Factors

                        in Hereditary Endometrial Cancer


Lunch and Poster Session


Session 3: Hereditary Cancer ModelsChair: Jim Ford and Gabriel Capellá

Hereditary Cancer Syndromes often are extremely good models for the understanding the molecular biology of cancer. On top of that, the development of relevant cancer models is critical to further understand these cancer predisposition syndromes to develop and analyze relevant animal models. Genetically modified animals and orthotopic implantation and perpetuation of human tumors provide complementary approaches. In this session examples of both approaches will be discussed.

15.30-15.35     Introduction
15.35-16.05     Jos Jonkers, Netherlands Cancer Institute, the Netherlands
                        Studying therapy response and resistance in mouse models of hereditary breast   cancer
16.05-16.35      Alberto Villanueva, Catalan Institute of Oncology (ICO), Spain
                         Development of personalized treatment strategies for hereditary cancer syndromes

16.35 - 16.55    Miguel Angel Pujana
                         Catalan Institute of Oncology (ICO), Spain
                         Linking Allosteric mTOR Inhibition Resistance to Breast Cancer Metastatic Potential



Short Break


Session 4: Hereditary Cancer: The State of the Art (I)Chair: Laura Valle and Antonis Antoniou

The objective of this session and session 5 is to put up to date the audience on the most recent knowledge and advances in the different aspects of hereditary cancers, with a special coverage of breast and colorectal hereditary cancers.

17.25 - 17.30     Introduction
17.30 - 18.00     Gabriel Capellá, Catalan Institute of Oncology (ICO), Spain
                          Hereditary Colorectal cancer: Functional characteristics of mismatch repair gene variants
18.00 - 18.30     Jim Ford, Stanford University School of Medicine, USA
                          Hereditary Breast Cancer: An Update on Genes and Genomes
18.30 - 18.50     Tereza Vaclova, Spanish National Cancer Center (CNIO), Spain
                          Role of haploinsufficiency of BRCA1 in DNA repair capacity, proliferation
                          and sensitivity of cells to PARP inhibitors


Friday 15 March


Session 5: Hereditary Cancer: The State of the Art (II)Chair: Katharina Wimmer and Jordi Surrallés

09.00-09.05     Introduction
09.05-09.35     Eduard Serra, IMPPC, Spain
                        Personalized Hereditary Cancer Genomics: Neurofibromatosis as an example
09.35-10.05     Hans F.A. Vasen, Leiden University Medical Centre, The Netherlands
                        Personalized surveillance programs for individuals with an inherited predisposition to develop
                        pancreatic cancer?

10.05-10.25     Clara Ruiz-Ponte, Fundación Pública Galega de Medicina Xenómica, Spain
                        CNVs in early-onset colorrectal cancer




Session 6: Cancer Susceptibility: Modifying Hereditary Cancer RiskChair: Javier Benitez and John Burn

The path from high penetrance genes to low penetrance genes has brought many challenges to the field of cancer genetics, not only for sporadic cancers but also for hereditary cancer. How do we quantify cancer risk out from whole genome analysis? How is the analysis of the whole genome changing the management of cancer risk in hereditary cancers?

10.55 - 11.00     Introduction
11.00 - 11.30     Cecile Janssens
                          Professor of Translational Epidemiology at the Department of Epidemiology
                          Emory University in Atlanta, USA
                          Cancer susceptibility: how predictive is our DNA?
11.30 - 12.00     Antonis Antoniou
                          University of Cambridge, UK
                          Modelling genetic susceptibility to breast and ovarian cancer
12.00 - 12.20     Pal Moller
                          Research group inherited cancer, Oslo University Hospital

                          The Norwegian Radium Hospital, Norway
                          Prospectively observed breast cancer risk by age breast cancer
                          kindreds with or without BRCA mutation



Lunch and Posters


Session 7: Managing And Counseling Hereditary Cancer Patients In The Context Of Personal GenomesChair: Pal Moller and Judith Balmaña

The current power of being able to analyze full personal genomes is not only putting challenges to molecular geneticists or genetic epidemiologists, but also and specially to clinical geneticists, genetic counselors, ethical committees, and in general to any clinical professional working in medical aspects that will be shaken by personalized genomics. All these different topics will be covered, also in light of direct to consumer personalized genomics.

13.55 - 14.00     Introduction
14.00 - 14.30     Ignacio Blanco
                           Catalan Institute of Oncology (ICO), Spain
                          Cancer Genetic counseling for personalized medicine; one size does not fit all
14.30 - 15.00     Martina Cornel
                          VU Medical Center, The Netherlands
                          Public Health Gen-ethics in familial cancer in the personal genomics era
15.00 - 15.20     Clare Moynihan
                          Royal Marsden NHS Foundation Trust & Institute of Cancer Research, UK
                          "Not out of the woods": men's interpretations of undergoing genetic
                          profiling to determine future risk of prostate cancer



Short Break


Session 8: Therapeutic Approaches For Hereditary CancerChair: Joan Brunet and Martina Cornel

As more targeted therapies make their way to the clinics, tumors arising in patients in cancer syndromes show distinct features that may make them respond to specific therapies. Drugs with therapeutic and preventative efficacy are currently being evaluated. In the session the role of novel agents in treatment of these patients as well as the role of new and old drugs in chemoprevention will be discussed.

15.55 - 16.00     Introduction
16.00 - 16.30     Judith Balmaña, Hospital Vall d’Hebron, Spain
                         Challenges in the path to Personalized Medicine: the case
                          of PARP inhibitors in BRCA-associated cancers

16.30 - 17.00     John Burn, Institute of Genetic Medicine, Newcastle University, UK
                         The role of nanowire technology and aspirin in prevention of hereditary cancer
17.00 - 17.20     Elke Holinski-Feder, Ludwig-Maximilians-Universität, Munich, Germany and
                         Medical Genetic Center Munich, Germany
                         Long term chemoprevention in FAP


Closing Remarks